000			02991cam a2200421 i 4500
999			_c20032 _d20032
001			17746819
003			OSt
005			20250925070933.0
008			130521s2014 enka b 001 0 eng
010			_a 2013012165
020			_a9780443112201 _qhardback
035			_a17746819
040			_aDLC _beng _cDLC _erda _dDLC
042			_apcc
050	0	0	_aRC268.4 _b.M675 2014
082	0	0	_a616.994 _223
100			_aBocklage Therese
245	0	0	_aMolecular oncology
250			_a3rd ed
260			_aPhiladephia _bElsevier _c2024
300			_axix,969p _bcolor illustrations ; _c29 cm
336			_atext _2rdacontent
337			_aunmediated _2rdamedia
338			_avolume _2rdacarrier
504			_aIncludes bibliographical references and index.
505	8		_aMachine generated contents note: Part I; Part II; Part III; Part IV. Pharmacologic Targeting of Oncogenic Pathways.
520			_a"The genomic era has allowed enormous strides in our understanding of the molecular changes that underlie malignant transformation. Mutations have been discovered that are critical drivers of large cross-sections of human cancers. These discoveries have allowed us to find drugs that target these drivers and make important strides in treatment. Genomics and high-throughput technologies have illuminated the complexity of cancer and the facility with which cancers adapt during their natural history. The field is evolving rapidly with new discoveries and new drugs reported monthly. This book is a timely foundation for understanding in context the origins of molecular oncology and its future directions. The content reviews available technologies for the analysis of cancer tissues and genes; summaries of key oncogenic pathways from a molecular perspective; the technologies, pathways and targeted therapies of a wide range of human malignancies; and new pharmacologic therapies that have a common mechanistic target"-- _cProvided by publisher.
520			_a"This book was conceived more than five years before its publication date. It was intended to provide a resource that summarized technology, biochemistry, molecular pathophysiology, and targeted therapeutics. As contributors were being recruited and chapters written the field that was being described changed at an accelerating pace. It is a tribute to scientific progress that volumes like this one are out-of-date as they are published, but books like this are not meant to contain the most current laboratory discovery or report the most recent FDA approval"-- _cProvided by publisher.
650		0	_aCancer _xMolecular aspects.
650		0	_aTumor markers.
650		0	_aCarcinogenesis.
700	1		_aGelmann, Edward P., _d1953-
700	1		_aSawyers, Charles L.
700	1		_aRauscher, F. J. _q(Frank Joseph), _d1957-
906			_a7 _bcbc _corignew _d1 _eecip _f20 _gy-gencatlg
942			_2ddc _cBK